INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER

The invention relates to an inducer of senescence, in combination with a short-lived, selective Death Receptor 5 (DR5) agonist, for use in a method of treating a patient suffering from a tumor. The invention further relates to a pharmaceutical composition, comprising a short-lived, selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumor, and to a selective, short- lived DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 21. Juli Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

BERNARDS RENE [VerfasserIn]
WANG LIQIN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-07-21, Last update posted on www.tib.eu: 2023-12-08, Last updated: 2023-12-15

Patentnummer:

WO2022154664

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA014363224